 | • レポートコード：MRC23Q38333 • 出版社/出版日：QYResearch / 2023年3月 • レポート形態：英文、PDF、92ページ • 納品方法：Eメール（2-3日） • 産業分類：医薬品 |
| Single User | ￥435,000 (USD2,900) | ▷ お問い合わせ |
| Enterprise License | ￥870,000 (USD5,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本調査レポートは世界のプロトロンビン複合体濃縮物（PCC）医薬品市場について調査・分析し、世界のプロトロンビン複合体濃縮物（PCC）医薬品市場概要、メーカー別競争状況、地域別市場規模、タイプ別セグメント分析（500 IU/バイアル、600 IU/バイアル、1000 IU/バイアル、その他）、用途別セグメント分析（血友病B、ビタミンK欠乏症、その他）、主要企業のプロファイル、市場動向などに関する情報を掲載しています。主要企業としては、Takeda、CSL Behring GmbH、Grifols Biologicals、Octapharma、Hualan Biological、Meheco Xinxing Pharmaなどが含まれています。 世界のプロトロンビン複合体濃縮物（PCC）医薬品市場は、2022年にXXX米ドル、2029年にはXXX米ドルに達すると予測され、予測期間の年平均成長率はXXX％です。COVID-19とロシア・ウクライナ戦争の影響は、プロトロンビン複合体濃縮物（PCC）医薬品市場規模を推定する際に考慮しました。本レポートは、プロトロンビン複合体濃縮物（PCC）医薬品の世界市場を定量的・定性的な分析により包括的に提示し、読者がビジネス/成長戦略を策定し、市場競争状況を把握し、現在の市場における自社のポジションを分析し、プロトロンビン複合体濃縮物（PCC）医薬品に関するビジネス上の意思決定に役立てることを目的としています。 ・プロトロンビン複合体濃縮物（PCC）医薬品市場の概要 - 製品の定義 - プロトロンビン複合体濃縮物（PCC）医薬品のタイプ別セグメント - 世界のプロトロンビン複合体濃縮物（PCC）医薬品市場規模：タイプ別分析（500 IU/バイアル、600 IU/バイアル、1000 IU/バイアル、その他） - プロトロンビン複合体濃縮物（PCC）医薬品の用途別セグメント - 世界のプロトロンビン複合体濃縮物（PCC）医薬品市場規模：用途別分析（血友病B、ビタミンK欠乏症、その他） - 世界のプロトロンビン複合体濃縮物（PCC）医薬品市場規模予測（2018年-2029年） - プロトロンビン複合体濃縮物（PCC）医薬品の平均価格推移（2018年-2029年） - 前提条件と制限事項 ・メーカー別競争状況 - メーカー別市場シェア - 世界の主要メーカー、業界ランキング分析 - メーカー別平均価格 - プロトロンビン複合体濃縮物（PCC）医薬品市場の競争状況およびトレンド ・プロトロンビン複合体濃縮物（PCC）医薬品の地域別市場規模 - 北米のプロトロンビン複合体濃縮物（PCC）医薬品市場規模（2018年-2029年） - アメリカのプロトロンビン複合体濃縮物（PCC）医薬品市場規模（2018年-2029年） - ヨーロッパのプロトロンビン複合体濃縮物（PCC）医薬品市場規模（2018年-2029年） - アジア太平洋のプロトロンビン複合体濃縮物（PCC）医薬品市場規模（2018年-2029年） - 中国のプロトロンビン複合体濃縮物（PCC）医薬品市場規模（2018年-2029年） - 日本のプロトロンビン複合体濃縮物（PCC）医薬品市場規模（2018年-2029年） - 韓国のプロトロンビン複合体濃縮物（PCC）医薬品市場規模（2018年-2029年） - インドのプロトロンビン複合体濃縮物（PCC）医薬品市場規模（2018年-2029年） - オーストラリアのプロトロンビン複合体濃縮物（PCC）医薬品市場規模（2018年-2029年） - 中南米のプロトロンビン複合体濃縮物（PCC）医薬品市場規模（2018年-2029年） - 中東・アフリカのプロトロンビン複合体濃縮物（PCC）医薬品市場規模（2018年-2029年） ・タイプ別セグメント：500 IU/バイアル、600 IU/バイアル、1000 IU/バイアル、その他 - 世界のプロトロンビン複合体濃縮物（PCC）医薬品のタイプ別販売量（2018年-2023年） - 世界のプロトロンビン複合体濃縮物（PCC）医薬品のタイプ別売上（2018年-2023年） - 世界のプロトロンビン複合体濃縮物（PCC）医薬品のタイプ別価格 ・用途別セグメント：血友病B、ビタミンK欠乏症、その他 - 世界のプロトロンビン複合体濃縮物（PCC）医薬品の用途別販売量（2018年-2023年） - 世界のプロトロンビン複合体濃縮物（PCC）医薬品の用途別売上（2018年-2023年） - 世界のプロトロンビン複合体濃縮物（PCC）医薬品の用途別価格 ・主要企業のプロファイル：企業情報、事業概要、売上、製品ポートフォリオ、動向 Takeda、CSL Behring GmbH、Grifols Biologicals、Octapharma、Hualan Biological、Meheco Xinxing Pharma ・産業チェーンと販売チャネルの分析 - プロトロンビン複合体濃縮物（PCC）医薬品産業チェーン分析 - プロトロンビン複合体濃縮物（PCC）医薬品の主要原材料 - プロトロンビン複合体濃縮物（PCC）医薬品の販売チャネル - プロトロンビン複合体濃縮物（PCC）医薬品のディストリビューター - プロトロンビン複合体濃縮物（PCC）医薬品の主要顧客 ・プロトロンビン複合体濃縮物（PCC）医薬品市場ダイナミクス - プロトロンビン複合体濃縮物（PCC）医薬品の業界動向 - プロトロンビン複合体濃縮物（PCC）医薬品市場の成長ドライバ、課題、阻害要因 ・調査成果および結論 ・調査方法とデータソース |
Highlights
The global Prothrombin Complex Concentrate (PCC) Drug market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Netherlands-Ukraine War were considered while estimating market sizes.
North American market for Prothrombin Complex Concentrate (PCC) Drug is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
Asia-Pacific market for Prothrombin Complex Concentrate (PCC) Drug is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The key global manufacturers of Prothrombin Complex Concentrate (PCC) Drug include Takeda, CSL Behring GmbH, Grifols Biologicals, Octapharma, Hualan Biological and Meheco Xinxing Pharma, etc. in 2022, the world’s top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Prothrombin Complex Concentrate (PCC) Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Prothrombin Complex Concentrate (PCC) Drug.
The Prothrombin Complex Concentrate (PCC) Drug market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Prothrombin Complex Concentrate (PCC) Drug market comprehensively. Regional market sizes, concerning products by type, by application and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Prothrombin Complex Concentrate (PCC) Drug manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by type, by application and by regions.
By Company
Takeda
CSL Behring GmbH
Grifols Biologicals
Octapharma
Hualan Biological
Meheco Xinxing Pharma
Segment by Type
500 IU/Vial
600 IU/Vial
1000 IU/Vial
Others
Segment by Application
Hemophilia B
Vitamin K Deficiency
Others
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Prothrombin Complex Concentrate (PCC) Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Prothrombin Complex Concentrate (PCC) Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
1 Prothrombin Complex Concentrate (PCC) Drug Market Overview
1.1 Product Overview and Scope of Prothrombin Complex Concentrate (PCC) Drug
1.2 Prothrombin Complex Concentrate (PCC) Drug Segment by Type
1.2.1 Global Prothrombin Complex Concentrate (PCC) Drug Market Value Comparison by Type (2023-2029)
1.2.2 500 IU/Vial
1.2.3 600 IU/Vial
1.2.4 1000 IU/Vial
1.2.5 Others
1.3 Prothrombin Complex Concentrate (PCC) Drug Segment by Application
1.3.1 Global Prothrombin Complex Concentrate (PCC) Drug Market Value by Application: (2023-2029)
1.3.2 Hemophilia B
1.3.3 Vitamin K Deficiency
1.3.4 Others
1.4 Global Prothrombin Complex Concentrate (PCC) Drug Market Size Estimates and Forecasts
1.4.1 Global Prothrombin Complex Concentrate (PCC) Drug Revenue 2018-2029
1.4.2 Global Prothrombin Complex Concentrate (PCC) Drug Sales 2018-2029
1.4.3 Global Prothrombin Complex Concentrate (PCC) Drug Market Average Price (2018-2029)
1.5 Assumptions and Limitations
2 Prothrombin Complex Concentrate (PCC) Drug Market Competition by Manufacturers
2.1 Global Prothrombin Complex Concentrate (PCC) Drug Sales Market Share by Manufacturers (2018-2023)
2.2 Global Prothrombin Complex Concentrate (PCC) Drug Revenue Market Share by Manufacturers (2018-2023)
2.3 Global Prothrombin Complex Concentrate (PCC) Drug Average Price by Manufacturers (2018-2023)
2.4 Global Prothrombin Complex Concentrate (PCC) Drug Industry Ranking 2021 VS 2022 VS 2023
2.5 Global Key Manufacturers of Prothrombin Complex Concentrate (PCC) Drug, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Prothrombin Complex Concentrate (PCC) Drug, Product Type & Application
2.7 Prothrombin Complex Concentrate (PCC) Drug Market Competitive Situation and Trends
2.7.1 Prothrombin Complex Concentrate (PCC) Drug Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Prothrombin Complex Concentrate (PCC) Drug Players Market Share by Revenue
2.7.3 Global Prothrombin Complex Concentrate (PCC) Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Prothrombin Complex Concentrate (PCC) Drug Retrospective Market Scenario by Region
3.1 Global Prothrombin Complex Concentrate (PCC) Drug Market Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global Prothrombin Complex Concentrate (PCC) Drug Global Prothrombin Complex Concentrate (PCC) Drug Sales by Region: 2018-2029
3.2.1 Global Prothrombin Complex Concentrate (PCC) Drug Sales by Region: 2018-2023
3.2.2 Global Prothrombin Complex Concentrate (PCC) Drug Sales by Region: 2024-2029
3.3 Global Prothrombin Complex Concentrate (PCC) Drug Global Prothrombin Complex Concentrate (PCC) Drug Revenue by Region: 2018-2029
3.3.1 Global Prothrombin Complex Concentrate (PCC) Drug Revenue by Region: 2018-2023
3.3.2 Global Prothrombin Complex Concentrate (PCC) Drug Revenue by Region: 2024-2029
3.4 North America Prothrombin Complex Concentrate (PCC) Drug Market Facts & Figures by Country
3.4.1 North America Prothrombin Complex Concentrate (PCC) Drug Market Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America Prothrombin Complex Concentrate (PCC) Drug Sales by Country (2018-2029)
3.4.3 North America Prothrombin Complex Concentrate (PCC) Drug Revenue by Country (2018-2029)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Prothrombin Complex Concentrate (PCC) Drug Market Facts & Figures by Country
3.5.1 Europe Prothrombin Complex Concentrate (PCC) Drug Market Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe Prothrombin Complex Concentrate (PCC) Drug Sales by Country (2018-2029)
3.5.3 Europe Prothrombin Complex Concentrate (PCC) Drug Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Prothrombin Complex Concentrate (PCC) Drug Market Facts & Figures by Country
3.6.1 Asia Pacific Prothrombin Complex Concentrate (PCC) Drug Market Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific Prothrombin Complex Concentrate (PCC) Drug Sales by Country (2018-2029)
3.6.3 Asia Pacific Prothrombin Complex Concentrate (PCC) Drug Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Prothrombin Complex Concentrate (PCC) Drug Market Facts & Figures by Country
3.7.1 Latin America Prothrombin Complex Concentrate (PCC) Drug Market Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America Prothrombin Complex Concentrate (PCC) Drug Sales by Country (2018-2029)
3.7.3 Latin America Prothrombin Complex Concentrate (PCC) Drug Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Prothrombin Complex Concentrate (PCC) Drug Market Facts & Figures by Country
3.8.1 Middle East and Africa Prothrombin Complex Concentrate (PCC) Drug Market Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa Prothrombin Complex Concentrate (PCC) Drug Sales by Country (2018-2029)
3.8.3 Middle East and Africa Prothrombin Complex Concentrate (PCC) Drug Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global Prothrombin Complex Concentrate (PCC) Drug Sales by Type (2018-2029)
4.1.1 Global Prothrombin Complex Concentrate (PCC) Drug Sales by Type (2018-2023)
4.1.2 Global Prothrombin Complex Concentrate (PCC) Drug Sales by Type (2024-2029)
4.1.3 Global Prothrombin Complex Concentrate (PCC) Drug Sales Market Share by Type (2018-2029)
4.2 Global Prothrombin Complex Concentrate (PCC) Drug Revenue by Type (2018-2029)
4.2.1 Global Prothrombin Complex Concentrate (PCC) Drug Revenue by Type (2018-2023)
4.2.2 Global Prothrombin Complex Concentrate (PCC) Drug Revenue by Type (2024-2029)
4.2.3 Global Prothrombin Complex Concentrate (PCC) Drug Revenue Market Share by Type (2018-2029)
4.3 Global Prothrombin Complex Concentrate (PCC) Drug Price by Type (2018-2029)
5 Segment by Application
5.1 Global Prothrombin Complex Concentrate (PCC) Drug Sales by Application (2018-2029)
5.1.1 Global Prothrombin Complex Concentrate (PCC) Drug Sales by Application (2018-2023)
5.1.2 Global Prothrombin Complex Concentrate (PCC) Drug Sales by Application (2024-2029)
5.1.3 Global Prothrombin Complex Concentrate (PCC) Drug Sales Market Share by Application (2018-2029)
5.2 Global Prothrombin Complex Concentrate (PCC) Drug Revenue by Application (2018-2029)
5.2.1 Global Prothrombin Complex Concentrate (PCC) Drug Revenue by Application (2018-2023)
5.2.2 Global Prothrombin Complex Concentrate (PCC) Drug Revenue by Application (2024-2029)
5.2.3 Global Prothrombin Complex Concentrate (PCC) Drug Revenue Market Share by Application (2018-2029)
5.3 Global Prothrombin Complex Concentrate (PCC) Drug Price by Application (2018-2029)
6 Key Companies Profiled
6.1 Takeda
6.1.1 Takeda Corporation Information
6.1.2 Takeda Description and Business Overview
6.1.3 Takeda Prothrombin Complex Concentrate (PCC) Drug Sales, Revenue and Gross Margin (2018-2023)
6.1.4 Takeda Prothrombin Complex Concentrate (PCC) Drug Product Portfolio
6.1.5 Takeda Recent Developments/Updates
6.2 CSL Behring GmbH
6.2.1 CSL Behring GmbH Corporation Information
6.2.2 CSL Behring GmbH Description and Business Overview
6.2.3 CSL Behring GmbH Prothrombin Complex Concentrate (PCC) Drug Sales, Revenue and Gross Margin (2018-2023)
6.2.4 CSL Behring GmbH Prothrombin Complex Concentrate (PCC) Drug Product Portfolio
6.2.5 CSL Behring GmbH Recent Developments/Updates
6.3 Grifols Biologicals
6.3.1 Grifols Biologicals Corporation Information
6.3.2 Grifols Biologicals Description and Business Overview
6.3.3 Grifols Biologicals Prothrombin Complex Concentrate (PCC) Drug Sales, Revenue and Gross Margin (2018-2023)
6.3.4 Grifols Biologicals Prothrombin Complex Concentrate (PCC) Drug Product Portfolio
6.3.5 Grifols Biologicals Recent Developments/Updates
6.4 Octapharma
6.4.1 Octapharma Corporation Information
6.4.2 Octapharma Description and Business Overview
6.4.3 Octapharma Prothrombin Complex Concentrate (PCC) Drug Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Octapharma Prothrombin Complex Concentrate (PCC) Drug Product Portfolio
6.4.5 Octapharma Recent Developments/Updates
6.5 Hualan Biological
6.5.1 Hualan Biological Corporation Information
6.5.2 Hualan Biological Description and Business Overview
6.5.3 Hualan Biological Prothrombin Complex Concentrate (PCC) Drug Sales, Revenue and Gross Margin (2018-2023)
6.5.4 Hualan Biological Prothrombin Complex Concentrate (PCC) Drug Product Portfolio
6.5.5 Hualan Biological Recent Developments/Updates
6.6 Meheco Xinxing Pharma
6.6.1 Meheco Xinxing Pharma Corporation Information
6.6.2 Meheco Xinxing Pharma Description and Business Overview
6.6.3 Meheco Xinxing Pharma Prothrombin Complex Concentrate (PCC) Drug Sales, Revenue and Gross Margin (2018-2023)
6.6.4 Meheco Xinxing Pharma Prothrombin Complex Concentrate (PCC) Drug Product Portfolio
6.6.5 Meheco Xinxing Pharma Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Prothrombin Complex Concentrate (PCC) Drug Industry Chain Analysis
7.2 Prothrombin Complex Concentrate (PCC) Drug Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Prothrombin Complex Concentrate (PCC) Drug Production Mode & Process
7.4 Prothrombin Complex Concentrate (PCC) Drug Sales and Marketing
7.4.1 Prothrombin Complex Concentrate (PCC) Drug Sales Channels
7.4.2 Prothrombin Complex Concentrate (PCC) Drug Distributors
7.5 Prothrombin Complex Concentrate (PCC) Drug Customers
8 Prothrombin Complex Concentrate (PCC) Drug Market Dynamics
8.1 Prothrombin Complex Concentrate (PCC) Drug Industry Trends
8.2 Prothrombin Complex Concentrate (PCC) Drug Market Drivers
8.3 Prothrombin Complex Concentrate (PCC) Drug Market Challenges
8.4 Prothrombin Complex Concentrate (PCC) Drug Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer